The literature search produced 1,305 records, 66 of which were considered potentially relevant. The authors excluded 43 studies, leaving a total of 23 to be included in the review; therefore, 2,724 adult patients presenting to the ED with symptoms of an acute asthma exacerbation were enrolled in these studies selected for inclusion. All of the included studies compared the use of inhaled shortacting b-2 agonists with shortacting anticholinergics to inhaled short-acting b-2 agonists alone. The anticholinergic agent was ipratropium bromide in 19 of the studies. The remaining studies used either inhaled atropine sulfate or oxitropium bromide. Albuterol was the most commonly used b-2 agonist. Most medications were provided by nebulizer; however, 7 studies used a metered-dose inhaler. The majority of the studies were assessed to be at high or unclear risk of bias, whereas only one was determined to be at low risk of bias.
Overall, the addition of an anticholinergic agent was associated with decreased likelihood of hospitalization, improved pulmonary function testing, decreased relapse rates (ranging from 24 hours to 2 weeks), and increased risk of mild adverse events (Table) . Subgroup analysis suggested that the majority of the benefit with respect to hospitalization occurred in patients with severe 
STUDY SELECTION
The studies included in the systematic review were randomized or controlled clinical trials that compared the use of combined inhaled b-2 agonists with anticholinergics to inhaled b-2 agonists alone for patients presenting to the emergency department (ED) with acute asthma. 
Commentary
Asthma is a common disease, affecting more than 17.7 million adults in the United States.
2 Asthma exacerbations result in 1.8 million annual ED visits in the United States, with 11.9% of these patients being hospitalized. 3 Acute asthma exacerbations are typically treated with a combination of b-2 agonists and corticosteroid therapy. Although more commonly used for acute exacerbations of chronic obstructive pulmonary disorder, anticholinergic agents are also used for asthma exacerbation by some providers. Anticholinergic agents are suggested to be synergistic because they work through a different mechanism and have a longer half-life. 4, 5 This review demonstrated that the addition of anticholinergic agents to b-2 agonists decreased overall rates of hospitalization, with a 6.4% absolute reduction, corresponding to a number needed to treat of 16. Additionally, anticholinergic agents were associated with decreased relapse rates, improved lung function, and increased rates of adverse events. Most of the adverse events were mild and included symptoms such as dry mouth, tremor, and anxiety.
It is important to consider these findings in the context of the following limitations. Most studies were considered low to moderate quality because of inadequate reporting of various aspects of the protocols. Eight studies had pharmaceutical industry funding, which may have biased their conclusions. Additionally, most of the included studies were small, with moderate clinical heterogeneity in regard to patient characteristics, study settings, treatment dosing, and hospital admission criteria.
Future studies should compare single doses with multiple doses of anticholinergics, the effect on mild asthma exacerbations, and other outcomes, such as ED length of stay, quality of life, and symptom scores. 
